Cancer Chemotherapy and Pharmacology

, Volume 1, Issue 2, pp 83–90 | Cite as

The role of antitumor antibiotics in current oncologic practice

  • Hugh L. DavisJr.
  • Daniel D. von Hoff
  • Jane E. Henney
  • Marcel Rozencweig
Short Review Antibiotics
Received:
Accepted:

Summary

The antitumor antibiotics have thus made a major impact on oncologic practice. The continued search for productive strains of these organisms should be encouraged; in addition, the activity and toxicity spectrum suggests the need for vigorous analogue development. An active anthracycline devoid of cardiotoxicity, a bleomycin with no effect on pulmonary tissue, an analogue of streptozoticin devoid of nephrotoxicity —these would be advances of inestimable benefit to the cancer patient of the future.

Keywords

Cancer Patient Cancer Research Anthracycline Bleomycin Productive Strain 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Aisner, J., Esterhay, R. J., Jr., Wiernik, P. H. Treatment of oat cell carcinoma of the lung with cyclophosphamide, adriamycin, epipodophyllotoxin VP 16-213 and methanol extracted residue (MER) of BCG. Proc. Amer. Ass. Cancer Res., Amer. Soc. clin. Oncol. 17, 261 (1976)Google Scholar
  2. 2.
    Baehner, R. L., Bernstein, I. O., Higgins, G., McCreadie, S., Chard, R. L., Hammond, D.: Improved induction remission response in children with acute non-lymphocytic leukemia treated with daunomycin, 5-azacytidine, cytosine arabinoside, prednisone, and vincristine (D-ZAPO). Proc. Amer. Ass. Cancer Res., Amer. Soc. clin. Oncol. (in press, 1977)Google Scholar
  3. 3.
    Baker, L. H., Opipari, M. I., Izbicki, R. M.: Phase II study of mitomycin C, vincristine, and bleomycin in advanced squamous cell carcinoma of the uterine cervix. Cancer 38, 2222 (1976)Google Scholar
  4. 4.
    Benjamin, R. S., Hall, S. W., Burgess, M. A., Wheeler, W. L., Murphy, W. K., Blumenschein, G. R., Gottlieb, J. A.: A pharmacokinetically based phase I–II study of single dose actinomycin D (NSC-3053). Cancer treat. Rep. 60, 289 (1976)Google Scholar
  5. 5.
    Beretta, G., Bonnadonna, G., Cascinelli, N., Morabito, A., Veronesi, U.: Comparative evaluation of three combination regimens for advanced malignant melanoma; results of an international cooperative study. Cancer treat. Rep. 60, 33 (1976)Google Scholar
  6. 6.
    Billingham, M., Bristow, M., Mason, J., Friedman, M.: Endomyocardial biopsy findings in adriamycin treated patients. proc. Amer. Ass. Cancer Res., Amer. Soc. clin. Oncol. 17, 281 (1976)Google Scholar
  7. 7.
    Blum, R. H., Carter, S. K.: Adriamycin, a new anticancer drug with significant clinical activity. Ann. intern. Med. 80, 249 (1974)Google Scholar
  8. 8.
    Blum, R. H., Carter, S. K., Agre, K.: A clinical review of bleomycin: a new antineoplastic agent. Cancer 31, 903 (1973)Google Scholar
  9. 9.
    Bonnadonna, G., de Lena, M., Monfardini, S., Bartoli, C., Bajetta, E., Beretta, G., Fossati-Bellani, F.: Clinical trials with bleomycin in lymphomas and solid tumors. Europ. J. Cancer 8, 205 (1972)Google Scholar
  10. 10.
    Bonnadonna, G., Zucilli, R. Monfardini, S. de Lena, M., Uslenghi, C.: Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 36, 252 (1975)Google Scholar
  11. 11.
    Broder, L. E., Carter, S. K.: Pancreatic islet cell carcinoma II: results of therapy with streptozoticin in 52 patients. Ann. intern. Med. 79, 108 (1973)Google Scholar
  12. 12.
    Calendi, E., di Marco, A., Regiani, M., et al.: On physicochemical interactions between daunomycin and nucleic acids. Biochem. biophys. Acta (Amst.) 103, 25 (1965)Google Scholar
  13. 13.
    Carter, S. K., Wasserman, T. H.: The chemotherapy of urologic cancer. Cancer 36, 729 (1975)Google Scholar
  14. 14.
    Cohen, M. H., Hrushesky, W., Minna, J. D.: Chemotherapy response after initial treatment failure in small cell bronchogenic carcinoma. Proc. Amer. Ass. Cancer Res., Amer. Soc. clin. Oncol. 17, 112 (1976)Google Scholar
  15. 15.
    Cohen, M., Shaw, M. W., Craig, A. P.: The effects of streptonigrin in cultured human leucocytes. Proc. nat. Acad. Sci. (Wash.) 50, 16 (1963)Google Scholar
  16. 16.
    Cortez, E. P., Holland, J. F., Wang, J. J., Sinks, L. F., Blom, J., Senn, H., Bank, A., Glidewell, O.: Amputation and adriamycin in primary osteosarcoma. New Engl. J. Med. 291, 998 (1974)Google Scholar
  17. 17.
    Cryer, P. E., Hill, G. J., II: Pancreatic islet cell carcinoma with hypercalcemia and hypergastrinemia. Cancer 38, 2217 (1976)Google Scholar
  18. 18.
    Cvitkovic, E., Hayes, D., Golbey, R.: Primary combination chemotherapy (VAB III) for metastatic or unresectable germ cell tumors. Proc. Amer. Ass. Cancer Res., Amer. Soc. clin. Oncol. 17, 296 (1976)Google Scholar
  19. 19.
    Cvitkovic, E., Wittes, R., Golbey, R., Krakoff, I. H.: Primary combination chemotherapy (VAB II) for metastatic or unresectable germ cell tumors. Proc. Amer. Ass. Cancer Res., Amer. Soc. clin. Oncol. 16, 174 (1975)Google Scholar
  20. 20.
    D'Angio, G. J., Evans, A. E., Breslow, N., Beckwith, B., Bishop, H., Feigl, P., Goodwin, W., Leapi, L. L., Sinks, L. F., Sutow, W., Tefft, M., Wolff, J. The treatment of Wilms' tumor: results of the National Wilms' tumor study. Cancer 38, 633 (1976)Google Scholar
  21. 21.
    de Vita V. T., Canellos, G. P., Moxley, J. H., III: A decade of combination therapy of advanced Hodgkin's disease. Cancer 30, 1495 (1972)Google Scholar
  22. 22.
    de Lena, M., Brambilla, C., Morabito, A., Bonnadonna, G.: Adriamycin plus vincristine compared to and combined with cyclophosphamide, methotrexate, and 5-fluorouracil for advanced breast cancer. Cancer 35, 1108 (1975)Google Scholar
  23. 23.
    Einhorn, L. H., Donohue, J. P.: Improved chemotherapy in disseminated testicular cancer. J. Urol. (Baltimore) 117, 65 (1977)Google Scholar
  24. 24.
    Farber, S.: Chemotherapy in the treatment of leukemia and Wilm's tumor. J. Amer. med. Ass. 198, 826 (1966)Google Scholar
  25. 25.
    Frei, E., III: The clinical use of actinomycin. Cancer Chemother. Rep. 58, 49 (1974)Google Scholar
  26. 26.
    Gale, R. P., Cline, M. J.: High remission induction rate in acute myeloid leukemia. Lancet 1977 I, 497Google Scholar
  27. 27.
    Ghavini, F., Exelby, P. R., d'Angio, G. J., Cham, W., Lieberman, P. H., Tam, C., Miki, V., Murphy, M. L.: Multidisciplinary treatment of embryonal rhabdomyosarcoma in children. Cancer 35, 667 (1975)Google Scholar
  28. 28.
    Gottlieb, J. A., Baker, L. H., Burgess, M. A., Sinkovics, J. G., Moon, T., Bodey, G. P., Rodrigues, V., Rivkin, S. E., Saiki, J., O'Bryan, R. M.: Sarcoma chemotherapy. In: Cancer chemotherapy, pp. 445–454. Chicago: Yearbook Medical Publishers 1975Google Scholar
  29. 29.
    Hammond, C. B., Parker, R. T.: Diagnosis and treatment of trophoblastic disease; a report from the Southeastern Regional Center. Obstet. and Gynec. 35, 132 (1970)Google Scholar
  30. 30.
    Holland, J. F., Glidewell, O.: Chemotherapy of acute lymphocytic leukemia of childhood. Cancer 30, 1480 (1972)Google Scholar
  31. 31.
    Hoogstraten, B., Chairman of the Southwest Oncology Group: Personal communicationGoogle Scholar
  32. 32.
    Hoogstraten, B., George, S. L., Samal, B., Rivkin, S. E., Costanzi, J. J., Bonnet, J. D., Thigpen, T., Braine, H.: combination chemotherapy and adriamycin in patients with advanced breast cancer. Cancer 38, 13 (1976)Google Scholar
  33. 33.
    Hornback, N. B., Einhorn, L., Shidnia, H., Joe, B. T., Krause, M., Furnas, B.: Oat cell carcinoma of the lung. Cancer 37, 2658 (1976)Google Scholar
  34. 34.
    Jaffee, N., Frei, E., IV.: Osteogenia sarcoma: advances in treatment. CA-A Cancer Journal for Clinicians 26, 351 (1976)Google Scholar
  35. 35.
    Johnson, R. E., Brereton, H. D., Kent, C. H.: Small-cell carcinoma of the lung; attempt to remedy causes of past therapeutic failure. Lancet 1976 II, 289Google Scholar
  36. 36.
    Jones, B., Cuttner, J., Levy, R. N., Patterson, R. B., Kung, F., Pleuss, H. J., Falkson, G., Treat, C. L., Haurani, F., Burgert, E. O., Jr., Rosner, F., Carey, R. W., Lukens, J., Blom, J., Degnan, T. J., Wohl, H., Glidewell, O., Holland, J. F.: Daunorubicin (NSC-83142) versus daunorubicin plus prednisone (NSC-10023) versus daunorubicin plus vincristine (NSC-065) plus prednisone in advanced childhood acute leukemia. Cancer Chemother. Rep. 56, 729 (1972)Google Scholar
  37. 37.
    Jones, S. D., Durie, B. G. M., Salmon, S. E.: Combination chemotherapy with adriamycin and cyclophosphamide for advanced breast cancer. Cancer 36, 90 (1975)Google Scholar
  38. 38.
    Junod, A., Lambert, A. E., Stauffacher, W., Renold, A. E.: Diabetogenic action of streptozoticin: relationship of dose to metabolic response. J. clin. Invest. 48, 2129 (1969)Google Scholar
  39. 39.
    Kaziro, Y., Kamiyama, M.: Mechanism of action of chromomycin A3. II: inhibition of RNA polymerase reaction. J. Biochem. (Tokyo) 62, 424 (1967)Google Scholar
  40. 40.
    Kennedy, B. J.: Metabolic and toxic effects of mithramycin during tumor therapy. Amer. J. Med. 49, 494 (1970)Google Scholar
  41. 41.
    Kennedy, B. J.: Mithramycin therapy in advanced testicular neoplasma. Cancer 26, 755 (1970)Google Scholar
  42. 42.
    Kennedy, B. J.: Mithramycin therapy in advanced neoplasms. Cancer 30, 755 (1970)Google Scholar
  43. 43.
    Kirk, J. M.: The mode of action of actinomycin D. Biochem. biophys. Acta (Amst.) 42, 167 (1960)Google Scholar
  44. 44.
    Kovach, J. S., Moertel, C. G., Ahmann, D. L., et al.: Phase I study of chromomycin A3 (NSC-58514). Cancer Chemother. Rep. 57, 341 (1973)Google Scholar
  45. 45.
    Kushnor, J. P., Hansen, V. L., Hammar, S. P.: Cardiomyopathy after widely separated courses of adriamycin exacerbated by actinomycin D and mithramycin. Cancer 34, 1577 (1975)Google Scholar
  46. 46.
    Lefrak, E. A., Oiťha, T., Rosenblum, S., Gottlieb, J. A.: Clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 32, 302 (1973)Google Scholar
  47. 47.
    Lenaz, L., Page, J. A.: Cardiotoxicity of adriamycin and related anthracyclines. Cancer treat. Rev. 3, 111 (1976)Google Scholar
  48. 48.
    Lewis, J. L., Jr.: Chemotherapy of gestational choriocarcinoma. Cancer 30, 1517 (1972)Google Scholar
  49. 49.
    Li, M. C., Hertz, T., Spencer, D. B.: Effect of methotrexate therapy upon choriocarcinoma and chorioadenoma. Proc. Soc. exp. Biol. (N.Y.) 93, 361 (1976)Google Scholar
  50. 50.
    Li, M. C., Whitmore, W. F., Golbey, R., Grabstadt, H.: Effects of combined crug therapy on metastatic cancer of the testis. J. Amer. med. Ass. 174, 1291 (1960)Google Scholar
  51. 51.
    Livingston, R. B., Moore, T. N.: Combined modality treatment of oat cell carcinoma of the lung. Proc. Amer. Ass. Cancer Res., Amer. Soc. clin. Oncol. 17, 152 (1976)Google Scholar
  52. 52.
    Loo, R. V., Vaitkevicius, V. R., Reed, M. L., Vaughn, C. B.: Phase I trial of porfiromycin (NSC-56410). Cancer Chemother. Rep. 51, 497 (1967)Google Scholar
  53. 53.
    MacDonald, J., Schein, P., Ueno, W., Woolley, P.: 5-fluorouracil (5-FU), mitomycin-C (MMC) and adriamycin (ADR)-FAM: a new combination chemotherapy program for advanced gastric carcinoma. Proc. Amer. Ass. Cancer Res., Amer. Soc. clin. Oncol. 17, 264 (1976)Google Scholar
  54. 54.
    McCredie, K. B., Hewlett, J. S., Kennedy, A.: The chemoimmunotherapy of acute leukemia (CIAL), a cooperative group study. Proc. Amer. Ass. Cancer Res., Amer. Soc. clin. Oncol. 17, 239 (1976)Google Scholar
  55. 55.
    McKelvey, E. M., Gottlieb, J. A., Wilson, H. E., Haut, A., Talley, R. W., Stephens, R., Lane, M., Gamble, J. F., Jones, S. E., Grozea, P. N., Gutterman, J., Coltman, D., Jr., Moon, T. E.: Hydroxyldaunomycin (adriamycin) combination chemotherapy in malignant lymphoma. Cancer 38, 1484 (1976)Google Scholar
  56. 56.
    Moertel, C. G., Reitmeier, R. J., Hahn, R. G.: Mitomycin C therapy in advanced gastrointestinal cancer. J. Amer. med. Ass. 204, 1045 (1969)Google Scholar
  57. 57.
    Muggia, F. M., Heinemann, H. O.: Hypercalcemia associated with neoplastic disease. Ann. intern. Med. 73, 281 (1970)Google Scholar
  58. 58.
    Nesbit, M. E.: Ewing's sarcoma. CA-A Cancer Journal for Clinicians 26, 174 (1976)Google Scholar
  59. 59.
    O'Bryan, R. M., Luce, J. K., Talley, R. W., Gottlieb, J. A., Baker, L. H., Bonnadonna, G.: Phase II evaluation of adriamycin in human neoplasia. Cancer 32, 1 (1973)Google Scholar
  60. 60.
    Olweny, C. L. M., Toya, T., Katongole-Mbidde, E., Lwanga, S. K., Owor, R., Kyalwazi, S., Vogel, C. L.: Treatment of Kaposi's sarcoma by combination of actinomycin-D, vincristine and imidazole carboxamide (NSC-45338): results of a randomized clinical trial. Int. J. Cancer 14, 649 (1974)Google Scholar
  61. 61.
    Osathanondh, R. O., Goldstein, D. P., pastorfide, G. B.: Actinomycin D as the primary agent for gestational trophoblastic disease. Cancer 36, 863 (1975)Google Scholar
  62. 62.
    Perlia, C. P., Gubisch, N. J., Wolter, J., Edelberg, D., Dederick, M. M., Taylor, S. G., III: Mithramycin treatment of hypercalcemia. Cancer 30, 389 (1970)Google Scholar
  63. 63.
    Pomeroy, T. C., Johnson, R. E.: Combined modality therapy of Ewing's sarcoma. Cancer 35, 36 (1975)Google Scholar
  64. 64.
    Rai, K. R., Holland, J. F., Glidewell, O.: Improvement in remission induction therapy of acute myelocytic leukemia. Proc. Amer. Ass. Cancer Res. 16, 265 (1975)Google Scholar
  65. 65.
    Ramirez, G., Weiss, A., The Central Oncology Group: A phase II study of adriamycin: 5 FU given weekly in the treatment of solid tumors. Proc. Amer. Ass. Cancer Res., Amer. Soc. clin. Oncol. 17, 248 (1976)Google Scholar
  66. 66.
    Reusses, F.: Mode of action of streptozoticin. J. Bact. 105, 580 (1971)Google Scholar
  67. 67.
    Reynolds, R. D., Fisher, J. I., Jensen, P. A., Pajak, T. F., Bateman, J. R.: Phase I alternate-day dose study of chromomycin A3. Cancer treat. Rep. 60, 1251 (1976)Google Scholar
  68. 68.
    Ryan, W. G., Schwartz, T. B., Northrop, G.: Treatment of Paget's disease with mithramycin: further experiences. Seminars in Drug Treatment 2, 57 (1972)Google Scholar
  69. 69.
    Samuels, M. L., Boyle, L. E., Holoye, P. Y., Johnson, D. E.: Intermittent versus continuous infusion bleomycin in testicular cancer: a comparison of response and survival in embryonal carcinoma (class 2) and teratocarcinoma (class 3 & 4). Proc. Amer. Ass. Cancer Res., Amer. Soc. clin. Oncol. 17, 98 (1976)Google Scholar
  70. 70.
    Samuels, M. L., Holoye, P. Y., Johnson, D. E.: Bleomycin combination chemotherapy in the management of testicular neoplasia. Cancer 36, 318 (1975)Google Scholar
  71. 71.
    Schein, P. S., de Vita, V. T., Hubbard, S., Chabner, B. A., Canellas, G. P., Berard, C., Young, R. C.: Bleomycin, adriamycin, cyclophosphamide, vincristine and prednisone (BACOP): combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma. Ann. intern. Med. 85, 417 (1976)Google Scholar
  72. 72.
    Schein, P. S., O'Connell, M. J., Blom, J., Hubbard, S., Magrath, I. T., Bergevin, P., Wiernik, P. H., Ziegler, J. L., de Vita, V. T.: Clinical antitumor activity and toxicity of streptozoticin (NSC-85998). Cancer 34, 993 (1974)Google Scholar
  73. 73.
    Selawry, O. S.: Polychemotherapy with adriamycin (NSC-123127) in bronchogenic carcinoma. Cancer Chemother. Rep. 6, 353 (1975)Google Scholar
  74. 74.
    Slayton, R. E., Shruder, B. I., Elias, E., Horton, J., Perlia, C. P.: New approach to the treatment of hypercalcemia. The effect of short-term treatment with mithramycin. Clin. Pharmacol. Ther. 12, 832 (1971)Google Scholar
  75. 75.
    Smith, J. P., Rutledge, F.: Advances in chemotherapy for gynecologic cancer. Cancer 36, 669 (1975)Google Scholar
  76. 76.
    Somerville, P. J., Evans, R. A.: Actinomycin D in the treatment of Paget's disease of bone. Med. J. Aust. 2, 13 (1975)Google Scholar
  77. 77.
    Sutow, W. W., Gehan, E. A., Vietti, T. J., Frias, A. E., Dyment, O. G.: Multidrug chemotherapy in primary treatment of osteosarcoma. J. Bone Jt Surg. 58-A, 629 (1976)Google Scholar
  78. 78.
    Suzuki, M., Nagai, R., Yamaki, H., Tanaha, N., Umezawa, H.: Mechanism of action of bleomycin: studies with growing culture of bacterial and tumor cells. J. Antibiot. (Tokyo) 21, 379 (1968)Google Scholar
  79. 79.
    Szybalski, W., Eyer, V. N.: Crosslinking of DNA by enzymatically or chemically activated mitomycins and porfiromycins, bifunctionally “alkylating” antibiotics. Fed. Proc. 23, 946 (1964)Google Scholar
  80. 80.
    Tattersall, M. H., Sodergren, J. E., Dengupta, S. K., Trites, D. J., Modest, E. J., Frei, E., III: Pharmacokinetics of actinomycin D in patients with malignant melanoma. Clin. Pharmacol. Ther. 17, 701 (1975)Google Scholar
  81. 81.
    Tranum, B., Hoogstraten, B.: Adriamycin in combination for treatment of breast cancer. Proc. Amer. Ass. Cancer Res., Amer. Soc. clin. Oncol. 17, 242 (1976)Google Scholar
  82. 82.
    Umezawa, H.: Principles of antitumor antibiotic therapy. In: Cancer medicine, pp. 817–826. Holland, J. F., Frei, E., III, (Eds.). Philadelphia: Lea & Febiger 1973Google Scholar
  83. 83.
    Vogel, C. L., Clements, D., Wanume, A. K., Toya, T., Primack, A., Kyalwazi, S.: Phase II clinical trials of BCNU (NSC-409962) and bleomycin (NSC-125066) in the treatment of Kaposi's sarcoma. Cancer Chemother. Rep. 57, 325 (1973)Google Scholar
  84. 84.
    Vogel, C. L., Primack, A., Dhru, D., Briers, P., Owor, R., Kyalwazi, S. K.: Treatment of Kaposi's sarcoma with a combination of actinomycin D and vincristine. Cancer 31, 1382 (1973)Google Scholar
  85. 85.
    Vogel, C. L., Templeton, C. J., Templeton, A. C., Taylor, J. F., Kyalwazi, S. K.: Treatment of Kaposi's sarcoma with actinomycin-D and cyclophosphamide: results of a randomized clinical trial. Int. J. Cancer 8, 136 (1971)Google Scholar
  86. 86.
    von Hoff, D. D., Rozencweig, M., Layard, M., Slavik, M., Muggia, F. M.: Daunomycin-induced cardiotoxicity in children and adults: a review of 110 cases. Amer. J. Med. 62, 200 (1976)Google Scholar
  87. 87.
    von Hoff, D. D., Rozencweig, M., Slavik, M.: Daunomycin: an antitumor antibiotic with activity in acute leukemia. Kanser 6, 1 (1976)Google Scholar
  88. 88.
    Weiss, A. J., Metter, G. E., Fletcher, W. S., Wilson, W. L., Grage, T. B., Ramirez, G.: Studies on adriamycin using a weekly regimen demonstrating its clinical effectiveness and lack of cardiac toxicity. Cancer treat. Rep. 60, 813 (1976)Google Scholar
  89. 89.
    Yarbro, J. W., Barnum, C. P., Kennedy, B. J.: Mithramycin inhibition of RNA synthesis. Cancer Res. 26, 36 (1966)Google Scholar
  90. 90.
    Zbinden, G., Brandle, E.: Toxicologic screening of daunorubicin (NSC-82151), adriamycin (NSC-123127), and their derivatives in rats. Cancer Chemother. Rep. 59, 707 (1975)Google Scholar

Copyright information

© Springer-Verlag 1978

Authors and Affiliations

  • Hugh L. DavisJr.
    • 1
  • Daniel D. von Hoff
    • 1
  • Jane E. Henney
    • 1
  • Marcel Rozencweig
    • 1
  1. 1.7C University HospitalUniversity of WisconsinMadisonUSA

Personalised recommendations